Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LUNAR-CV
- Development stage
- Preclinical
- Lead developer
- Arcturus Therapeutics
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
01
Overview
LUNAR-CV is an investigational mRNA-based therapeutic candidate developed using Arcturus Therapeutics’ LUNAR lipid nanoparticle delivery platform for the treatment of cardiovascular diseases. It employs messenger RNA to drive in vivo expression of a therapeutic protein within target tissues, aiming to modify cardiovascular pathophysiology rather than simply alleviate symptoms.[3][13] As a nucleic acid medicine formulated in a proprietary lipid-mediated delivery system, LUNAR-CV is intended to enable efficient cellular uptake and translation of its encoded payload to achieve durable therapeutic benefit in cardiovascular indications.[3][13]
Beyond the preview
Go deeper on LUNAR-CV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LUNAR-CV.